The G6 system, which won approval in the U.S. as ‘fully interoperable’ with other medical devices, includes a redesigned applicator that inserts a small sensor below the user’s skin. The sensor measures glucose levels and sends the data to a display device via a transmitter, which can be worn for up to 10 days.
The next-gen transmitter has a 28% lower profile than the G5 system, according to Dexcom, to provide patients with a more comfortable option to wear throughout the day.
The monitor also warns users if their blood sugar levels climb dangerously high or fall below the desired range.
“The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM,” John Lister, Dexcom’s GM for EMEA, said in prepared remarks.
“We’re treading new ground,” CEO Kevin Sayer told Drug Delivery Business News earlier this year.
The company said the G6 will be available this month in the U.K. and Ireland. Other European countries can expect to see the product later this year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.